Femasys announces achievement of regulatory approvals in Australia, NZ

Femasys (FEMY) announces the achievement of regulatory approvals in Australia and New Zealand, NZ, for its next-generation infertility solutions: FemaSeed for first-line intratubal insemination treatment and FemVue for diagnostic evaluation. “Securing regulatory approvals in Australia and New Zealand mark another important step in expanding global access to our innovative infertility solutions,” said Kathy Lee-Sepsick, CEO and Founder of Femasys. “With FemaSeed and FemVue, we are delivering much-needed, first-line options that address critical gaps in care for women struggling with infertility. These milestones not only validate the clinical value of our platform but also create meaningful commercial opportunities as we continue to grow revenue and broaden our global footprint.”